頁籤選單縮合
題名 | 免疫檢查點抑制劑臨床特性及挑戰=Immune Checkpoint Inhibitors: Clinical Characteristics and Future Challenges |
---|---|
作者姓名(中文) | 鄭吉元; 蔡慈貞; 張文震; | 書刊名 | 藥學雜誌 |
卷期 | 35:4=141 2019.12[民108.12] |
頁次 | 頁20-25 |
分類號 | 418.29 |
關鍵詞 | 免疫檢查點抑制劑; Immune checkpoint inhibitor; Ipilimumab; Nivolumab; Pembrolizumab; |
語文 | 中文(Chinese) |
中文摘要 | 自2011 年第一個免疫檢查點抑制劑 (immune checkpoint inhibitors,ICIs) ipilimumab 核准用於治療黑色素細胞瘤,之後陸續有5 個 ICIs 上市。目前可使用的 ICIs 包括 CTLA-4 抑制劑、PD-1 抑制劑、PD-L1 抑制劑。ICIs 可治療多種不同的癌 症和提供較高比例的長期存活。ICIs 治療腫瘤的反應有可能會出現假性惡化 (pseudoprogression) 之非典型的治療反應模式,因此不要太早判定治療無效。使用 ICIs 引起 副作用因而停藥者,其原本的療效仍可持續。併用不同機轉的 ICIs 或是不同策略的 免疫治療,或是 ICIs 合併化療、標靶藥物、放射線,可使更多病人獲得治療反應。 ICIs 的未來挑戰包括:找到最適當的劑量和藥物組合、給藥順序、治療持續時間、最 佳的生物標記可作為預先評估 ICIs 的療效。 |
英文摘要 | Ipilimumab, the first immune checkpoint inhibitors (ICIs ), was approved for the treatment of melanoma in 2011, and five ICIs had been listed successively. Currently, available ICIs include CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. ICIs could be used to treat a broad range of cancer types and provide higher percentage of long-term survival. ICIs may show the atypical pattern of response as pseudo-progression, so do not confirm treatment failure of ICIs too early. Patients who stop ICIs because of adverse drug events generally maintain responses. ICIs with different mechanisms can be combined, and ICIs can be combined with other cancer immunotherapies, chemotherapy, targeted therapy, and radiation to transform more non-responders to responders. Future challenges for ICIs include the optimal dose and combinations, the order of administration, duration of treatment, and the best biomarker to predict the efficacy of ICIs. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。